WINT (Windtree Therapeutics) Additional Paid-In Capital: $880.78 Mil(As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Windtree Therapeutics Additional Paid-In Capital?

Windtree Therapeutics WINT Additional Paid-In Capital is $880.78 Mil as of Sep. 2025. The stock has 2 warning signs investors should review.


Windtree Therapeutics's quarterly additional paid-in capital increased from Mar. 2025 ($864.00 Mil) to Jun. 2025 ($867.94 Mil) and increased from Jun. 2025 ($867.94 Mil) to Sep. 2025 ($880.78 Mil).

Windtree Therapeutics's annual additional paid-in capital increased from Dec. 2022 ($837.60 Mil) to Dec. 2023 ($851.26 Mil) and increased from Dec. 2023 ($851.26 Mil) to Dec. 2024 ($859.66 Mil).

Windtree Therapeutics Additional Paid-In Capital Related Terms

Windtree Therapeutics Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Windtree Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windtree Therapeutics Additional Paid-In Capital Chart

Windtree Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 790.28 830.23 837.60 851.26 859.66

Windtree Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 856.27 859.66 864.00 867.94 880.78

Windtree Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $880.78 Mil mean?
Windtree Therapeutics (WINT) has a Additional Paid-In Capital of $880.78 Mil as of Sep. 2025. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Windtree Therapeutics and its competitors.
Is Windtree Therapeutics' Additional Paid-In Capital too high?
Windtree Therapeutics' current Additional Paid-In Capital is $880.78 Mil.
How does Windtree Therapeutics' Additional Paid-In Capital compare to LIPO and ITRMF?
Windtree Therapeutics' Additional Paid-In Capital of $880.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Windtree Therapeutics and its competitors. Windtree Therapeutics's current Additional Paid-In Capital is $880.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windtree Therapeutics stock overvalued right now?
Windtree Therapeutics (WINT) has a current Additional Paid-In Capital of $880.78 Mil. The current Additional Paid-In Capital is $880.78 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Windtree Therapeutics (WINT), the current Additional Paid-In Capital is $880.78 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Windtree Therapeutics Business Description

Address 2600 Kelly Road, Suite 100, Warrington, PA, USA, 18976-3622
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.